ACT presents solutions to foster greater participation in May issue.
Patient recruitment remains the largest impediment to clinical trials progress. Barriers to participation are numerous and as noted in this article, can be broken down into these buckets on the recruitment progression cycle—awareness, identification, information and consent, patient-centric operations, and accelerated regulatory approval. Each of these buckets or progressions contain a plethora of ideas, strategies, technologies, and choices. And at any one of these progressions, a potential participant can be lost.
The reality of patient recruitment is that its success depends on those myriad factors under the buckets, in addition to an individual’s behavior or personal beliefs. According to survey results in this white paper from IQVIA, “When asked what prevents them from participating in a trial, fears about their health and safety (62%) far outweighed concerns about time (37%), logistics (18%), and negative press about research (8%).” Further influences can be analyzed by gender, race, and ethnicity, all coalescing around choosing to participate.
In this issue, we present a fraction of the exhaustive list of options that currently exist to foster recruitment. Virtual waiting rooms, for example, where potential participants can learn, discuss, and express interest in a clinical trial for a near-future opportunity to participate and remain engaged. Sharing clinical trial results with pediatric patients is a way to engage younger generations, as well as their parents or caregivers by providing transparency into the process. Tufts CSDD offers advice to sponsors and CROs on how to re-prioritize routine assessment of patient satisfaction as a primary outcome measure. And our main feature offers an overview of recent technologies such as patient opt-in solutions; EMR funnels to find appropriate patients for outreach by physicians; and solutions that find and monitor participants in the community via pharmacies such as CVS or Walgreens.
In this issue, we purposely did not highlight decentralized trials, which offers components that improve patient participation and experience under the patient-centric operations bucket.
Starting or piloting any new initiative to increase patient recruitment is a plus. Whatever you can do to increase the exposure and access for the potential of a clinical trial participation will help. Remember, “You miss 100% of the shots you don’t take.”
Lisa Henderson is Editor-in-Chief of Applied Clinical Trials. She can be reached at lhenderson@mjhlifesciences.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.